-
Notice of CDE of China NPMA on Issuing the Technical Guidance for CMC Changes of Innovative Drugs (Chemical Drugs) during Clinical Trials (Interim)
2021-03-15
The CDE, under the guidance of NMPA, has organized to formulate the Technical Guidance for CMC Changes of Innovative Drugs (Chemical Drugs) during Clinical Trials (Interim), which was issued and implemented as of March 3.
-
Notice of CDE of China NMPA on Issuing the Technical Requirements for CMC Study and Evaluation of Chemical Drugs Marketed Overseas But Not Marketed in China (Interim)
2021-03-09
The CDE, under the guidance of NMPA, has organized to formulate the Technical Requirements for CMC Study and Evaluation of Chemical Drugs Marketed Overseas But Not Marketed in China (Interim), which was issued and implemented as of March 3.
-
NMPA Notice on Issuing the Requirements for Change Items of Marketed Chemicals and Application Dossier
2021-02-10
To cooperate with the implementation of the Provisions for Drug Registration, the NMPA has organized to formulate the Requirements for Change Items of Marketed Chemicals and Application Dossier.
-
NMPA Announcement on Approval of Adding the Filing Function for the First Importation of Chemicals to the Chongqing Municipal Medical Products Administration
2021-02-07
The NMPA has approved the application of the Chongqing Municipal Medical Products Administration for adding the filing function for the first importation of chemicals, and this Announcement was hereby issued on February 2 as follows.
-
NMPA Announcement on Cancellation of 8 Certification Items
2021-02-05
As per the Notice of the General Office of the State Council on Effective Clearance of Certification Items, to further reduce redundant certification for the convenience of the people and optimize governmental service, the NMPA decided to cancel 8 certification items.
-
NMPA Announcement on Regulating Weian Capsules as Non-prescription Drugs
2021-02-01
According to the Provisions for the Classification Management of Prescription and Non-prescription Drugs (Interim), after the demonstration and review organized by the NMPA, the Weian Capsules are approved to be regulated as non-prescription drugs.
